Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label mass balance and pharmacokinetics study of [14C]MIJ821 in healthy male volunteers
NL-OMON51743Completed
- Sponsor
- Novartis
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of onfasprodil in major depressive disorder (MDD), sponsored by Novartis. Primary endpoints: Routes and rates of excretion and mass balance of drug-related radioactivity, Pharmacokinetics of total radioactivity in blood and plasma and 1 more. Started Apr 2022; status: completed.
02
Drugs
onfasprodil
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON51743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51743.